Latest Breaking News On - Karsten fischer - Page 1 : comparemela.com

Woodcock set to retire from FDA in early 2024—Chutes & Ladders

Woodcock set to retire from FDA in early 2024—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesJeremy caldwellGabrielle massonGraham owensCarole huntsmanEric perakslisNoema pharmaMano iyerMax bayerLisa shamonRamon felcianoRobert califfMichael kauffmanThomas heathmanAeglea biotherapeuticsWilliam shakespeare

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzKarsten fischerIntegra lifesciencesElias papatheodorouMike sinclairUniversity of utrechtManchester business schoolHeatmatrix groupChief executive officerMemo therapeuticsBusiness wireKyowa kirinStep pharmaLava therapeuticsManchester businessFast track

Memo Therapeutics AG Starts U S Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients

Memo Therapeutics AG Starts U S Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMike sinclairKarsten fischerDrug administrationFast trackChief medical officerMemo therapeuticsChief executive officerVakzine project managementNorth america

Memo Therapeutics granted FDA fast track for AntiBKV

Memo Therapeutics, a biotech company developing therapeutic antibodies, has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AntiBKV.

Karsten fischerFast trackBio developmentsFda approvalDrug deliveryFood and drug administration

FDA grants Memo Therapeutics fast track designation to treat transplant-related infection

Memo Therapeutics AG received fast track designation from the FDA for AntiBKV, a drug to treat BK polyomavirus infections, according to the press release.Currently, there are no therapeutics available to treat BK polyomavirus (BKV), an infection that commonly affects kidney transplant recipients. The infection, which typically occurs in childhood and remains dormant in healthy adults, can be

Karsten fischerGina brockenbroughMemo therapeutics